A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Participants With Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer

AbbVie

Status and phase

Terminated

Phase 1

Conditions

Acute Myeloid Leukemia (AML)

Treatments

Drug: ABBV-744

Study type

Interventional

Funder types

Industry

Identifiers

NCT03360006

M16-415

Details and patient eligibility

About

This is an open-label, Phase 1, dose-escalation (Segment 1) and expansion (Segment 2) study to determine the maximum tolerated dose (MTD) and/or the recommended phase two dose (RPTD), and to assess the safety, preliminary efficacy, and pharmacokinetic (PK) profile of ABBV-744 in participants with relapsed/refractory Acute Myeloid Leukemia (AML).

Enrollment

30 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Participant must have AML not amenable to curative therapy, refractory to standard of care therapy or for which standard of care therapy does not exist. Participants who are candidates for stem cell transplantation must have been offered this therapeutic option.
Must consent to provide biomarker analyses as described in the protocol.
Must have an Eastern Cooperative Oncology Group (ECOG) Performance status of:
- Dose Escalation (Segment 1): 0 - 1
- Dose Expansion (Segment 2): 0 - 2
Dose Escalation: Must have a serum albumin during Screening of >= 3.0 g/dL.
Participant has adequate bone marrow, renal and hepatic function.

Exclusion criteria

Participant with known active Central Nervous System (CNS) disease.
Participant has received anti-cancer traditional medicine or anti-cancer herbal remedies within 14 days prior to ABBV-744 dosing. Saw palmetto is considered anti-cancer herbal remedy. Participant has received anti-cancer therapy within a period of 14 days or 5 half-lives (whichever is longer; except for immunotherapy where a period of 21 days will be acceptable) prior to Study Day 1. Except for hydroxyurea which will be allowed during screening and treatment for controlling leukocytosis.
Participant has been previously treated with a Bromodomain and Extra-Terminal (BET) inhibitor
Participant has unresolved clinically significant toxicities from most recent prior anti-cancer therapy, defined as any Common Terminology Criteria for Adverse Events (CTCAE v 4.03) grade 2 or higher clinically significant toxicity (excluding alopecia).
Participant has received the following within 7 days prior to the first dose of study drug: corticosteroid therapy, CYP3A inhibitors, CYP3A inducers.
Participant consumed grapefruit or grapefruit products within 3 days prior to the first dose of study drug.
Participant had major surgery within 28 days prior to Study Day 1.
Participant is unable to swallow or absorb oral tablets.
Participant has known infection with hepatitis B or hepatitis C.
Participant has active peptic ulcer disease or other hemorrhagic esophagitis/gastritis, enteritis, colitis.
Participant has symptoms of gross hematuria or gross hemoptysis
Has electrocardiogram with a QT interval corrected for heart rate using Fridericia's formula (QTcF) > 470 msec or ECG with second degree type 2 or third degree atrioventricular block.